PODSTAVKOVÁ, N., Barbora WEINBERGEROVÁ, Anežka KVETKOVÁ, Michaela BOHÚNOVÁ, A. MAREČKOVÁ, Jana KOTAŠKOVÁ, Ivana JEŽÍŠKOVÁ, Michael DOUBEK and Jiří MAYER. Charakteristika a výsledky léčby Ropegenterferonem ALFA2B u pacientů s Ph negativními myeloproliferacemi. (Characteristics and results of treatment with Ropegenterferon ALFA2B in patients with Ph negative myeloproliferations). In XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Charakteristika a výsledky léčby Ropegenterferonem ALFA2B u pacientů s Ph negativními myeloproliferacemi.
Name (in English) Characteristics and results of treatment with Ropegenterferon ALFA2B in patients with Ph negative myeloproliferations
Authors PODSTAVKOVÁ, N. (203 Czech Republic), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Anežka KVETKOVÁ (703 Slovakia, belonging to the institution), Michaela BOHÚNOVÁ (703 Slovakia, belonging to the institution), A. MAREČKOVÁ (203 Czech Republic), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes, 2023.
Other information
Original language Czech
Type of outcome Conference abstract
Field of Study 30205 Hematology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/23:00131061
Organization unit Faculty of Medicine
Keywords in English Ph-negative myeloproliferations; Ropegenterferon ALFA2B treatment
Tags rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/3/2024 09:22.
Abstract
Charakteristika a výsledky léčby Ropegenterferonem ALFA2B u pacientů s Ph negativními myeloproliferacemi - konferenční abstrakt.
Abstract (in English)
Characteristics and results of Ropegenterferon ALFA2B treatment in patients with Ph-negative myeloproliferations - conference abstract.
Links
LX22NPO5102, research and development projectName: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
MUNI/A/1224/2022, interní kód MUName: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X
Investor: Masaryk University
PrintDisplayed: 20/7/2024 14:18